Total Payments
$290,555
2024 Payments
$77,817
Companies
111
Transactions
2,105
Medicare Patients
12,384
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$151,998 (52.3%)
Research$56,610 (19.5%)
Food & Beverage$39,502 (13.6%)
Travel$24,475 (8.4%)
Consulting$17,268 (5.9%)
Education$702.14 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $121,311 | 63 | 41.8% |
| Unspecified | $56,610 | 44 | 19.5% |
| Food and Beverage | $39,502 | 1,850 | 13.6% |
| Honoraria | $26,300 | 13 | 9.1% |
| Travel and Lodging | $24,475 | 81 | 8.4% |
| Consulting Fee | $17,268 | 7 | 5.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,388 | 3 | 1.5% |
| Education | $702.14 | 44 | 0.2% |
Payments by Type
General
$233,944
2,061 transactions
Research
$56,610
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $40,646 | 46 | $0 (2023) |
| SK Life Science, Inc. | $28,223 | 123 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $25,444 | 28 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $25,255 | 39 | $0 (2024) |
| ABBVIE INC. | $20,062 | 130 | $0 (2024) |
| Allergan, Inc. | $19,077 | 89 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $18,422 | 119 | $0 (2024) |
| Eisai Inc. | $16,390 | 61 | $0 (2024) |
| Lilly USA, LLC | $16,298 | 35 | $0 (2024) |
| Acorda Therapeutics, Inc | $12,643 | 30 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77,817 | 305 | Teva Pharmaceuticals USA, Inc. ($16,659) |
| 2023 | $30,052 | 274 | AbbVie Inc. ($11,802) |
| 2022 | $26,450 | 287 | SK Life Science, Inc. ($9,632) |
| 2021 | $21,778 | 315 | SK Life Science, Inc. ($8,142) |
| 2020 | $28,199 | 222 | Allergan, Inc. ($11,431) |
| 2019 | $17,503 | 211 | Acorda Therapeutics, Inc ($10,442) |
| 2018 | $22,415 | 225 | ACADIA Pharmaceuticals Inc ($9,684) |
| 2017 | $66,341 | 266 | ACADIA Pharmaceuticals Inc ($30,406) |
All Payment Transactions
2,105 individual payment records from CMS Open Payments — Page 1 of 85
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | NEUROPACE, INC. | RNS Neurostimulator Kit (Device) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Epilepsy | ||||||
| 12/24/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/20/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $34.91 | General |
| 12/19/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: Neurology | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/19/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $1.04 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,268.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: NEUROLOGY | ||||||
| 12/15/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Neurology | ||||||
| 12/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: PAIN | ||||||
| 12/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $741.12 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.08 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Neuropsychiatry | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,236.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/06/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $6.44 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: EPILEPSY | ||||||
| 12/04/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $122.06 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $1.01 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-032 | ACADIA Pharmaceuticals Inc | $29,157 | 11 |
| ACP-103-033 | ACADIA Pharmaceuticals Inc | $10,776 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $5,683 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $2,290 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $2,016 | 2 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $1,664 | 3 |
| LX9211 | Lexicon Pharmaceuticals, Inc. | $1,622 | 3 |
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $1,605 | 11 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $656.00 | 3 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $656.00 | 3 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $465.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $20.00 | 1 |
| ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $0.64 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 3,624 | 5,425 | $1.2M | $606,848 |
| 2022 | 18 | 3,292 | 4,930 | $1.4M | $518,292 |
| 2021 | 20 | 2,905 | 4,576 | $1.3M | $484,979 |
| 2020 | 18 | 2,563 | 4,177 | $1.1M | $355,456 |
Total Patients
12,384
Total Services
19,108
Medicare Billing
$2.0M
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 973 | 1,877 | $364,231 | $184,316 | 50.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 310 | 315 | $222,020 | $117,824 | 53.1% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 280 | 284 | $122,404 | $65,424 | 53.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 502 | 693 | $95,004 | $47,147 | 49.6% |
| 99424 | Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | Office | 2023 | 333 | 629 | $76,738 | $38,772 | 50.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 278 | 278 | $69,778 | $35,895 | 51.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 148 | 355 | $53,960 | $28,495 | 52.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 158 | 158 | $52,298 | $27,691 | 52.9% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 118 | 119 | $24,633 | $13,115 | 53.2% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 182 | 225 | $20,700 | $10,587 | 51.1% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 61 | 61 | $16,531 | $8,867 | 53.6% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 16 | 27 | $14,688 | $4,399 | 29.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 30 | $8,130 | $4,358 | 53.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 11 | 35 | $8,678 | $4,079 | 47.0% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 25 | 92 | $6,900 | $3,638 | 52.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 66 | 69 | $14,140 | $2,886 | 20.4% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 25 | 25 | $4,900 | $2,620 | 53.5% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2023 | 22 | 22 | $7,744 | $2,282 | 29.5% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 17 | 53 | $3,445 | $1,803 | 52.3% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 28 | 28 | $3,080 | $1,157 | 37.6% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 32 | 34 | $1,974 | $979.88 | 49.6% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 11 | 16 | $1,368 | $514.15 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 976 | 1,953 | $530,955 | $194,115 | 36.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 175 | 177 | $172,687 | $66,895 | 38.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 305 | 305 | $105,875 | $38,576 | 36.4% |
About Dr. Perminder Bhatia, MD
Dr. Perminder Bhatia, MD is a Neurology healthcare provider based in Fresno, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013002328.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Perminder Bhatia, MD has received a total of $290,555 in payments from pharmaceutical and medical device companies, with $77,817 received in 2024. These payments were reported across 2,105 transactions from 111 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($121,311).
As a Medicare-enrolled provider, Bhatia has provided services to 12,384 Medicare beneficiaries, totaling 19,108 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Fresno, CA
- Active Since 10/03/2006
- Last Updated 08/05/2009
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1013002328
Products in Payments
- NUPLAZID (Drug) $40,646
- ACTHAR (Biological) $25,777
- REXULTI (Drug) $25,242
- XCOPRI (Drug) $21,087
- UBRELVY (Drug) $18,383
- Austedo XR (Drug) $16,719
- Leqembi (Drug) $15,624
- KISUNLA (Drug) $15,214
- QULIPTA (Drug) $15,107
- INBRIJA (Drug) $12,344
- Cenobamate (Drug) $5,929
- NURTEC ODT (Drug) $5,884
- VNS Therapy (Device) $2,818
- Non-Covered Product (Drug) $2,073
- GENERAL DBS (Device) $1,818
- BAFIERTAM (Drug) $1,248
- GENERAL DBS (Device) $1,209
- Briviact (Drug) $1,172
- TYSABRI (Biological) $1,096
- MYOBLOC (Drug) $1,061
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fresno
Dr. Eric Farbman, M.d, M.D
Neurology — Payments: $950,053
Neurology $950,053
Dr. Melvin Helm, M.d, M.D
Neurology — Payments: $391,779
Neurology $391,779
Nighat Sarwar, M.d, M.D
Neurology — Payments: $191,325
Neurology $191,325
Cong Zhi Zhao, M.d, M.D
Neurology — Payments: $116,400
Neurology $116,400
Amir Khan, Md, MD
Neurology — Payments: $63,489
Neurology $63,489
Dr. Abbas Mehdi, M.d, M.D
Neurology — Payments: $45,578
Neurology $45,578